News - OxyDial Inc

Feb 19 2025

New Pediatric Breakthrough: Mitapivat Shows Efficacy in Treating PK Deficiency in Children

A recent Phase 3 trial (ACTIVATE-Kids) by Agios Pharmaceuticals demonstrated that mitapivat, an oral pyruvate kinase (PK) activator, significantly improved hemoglobin levels in children with PK deficiency who are not …

OxyDial

Feb 13 2025

New Combination Therapy by Astra Zeneca Shows Promise in Reducing Anemia in PNH Patients

A recent clinical trial published in Blood highlights a breakthrough in treating paroxysmal nocturnal hemoglobinuria (PNH). This rare, life-threatening blood disorder leads to the destruction of red blood cells. The …

OxyDial

Feb 7 2025

Emmaus Secures Market Exclusivity for Endari in Saudi Arabia

Emmaus Life Sciences has been granted market exclusivity for its sickle cell treatment, Endari® (L-glutamine oral powder), in the Kingdom of Saudi Arabia (KSA). The exclusivity, awarded by NUPCO, the …

OxyDial

Jan 31 2025

Novo Nordisk Expands Sickle Cell Pipeline with IMMvention’s Novel BACH1 Inhibitor Deal

In a strategic move to strengthen its position in the sickle cell disease market, Novo Nordisk has partnered with IMMvention Therapeutix, Inc. to co-develop innovative oral treatments. This collaboration focuses …

OxyDial

Jan 23 2025

Bristol Myers Squibb, Texas Children’s Global HOPE, and Baylor College of Medicine, Launch Program to Address Sickle Cell Disease in Sub-Saharan Africa

The Bristol Myers Squibb Foundation, Texas Children’s Global Health Network HOPE, and Baylor College of Medicine Global Health have announced a new initiative to combat sickle cell disease in Sub-Saharan …

OxyDial

Jan 17 2025

Agios Secures EC Endorsement for Sickle Cell Therapy

Agios Pharmaceuticals has announced that the European Commission (EC) has granted orphan medicinal product designation to their oral therapy, mitapivat, for treating sickle cell disease (SCD). Already recognized with orphan …

OxyDial

Dec 23 2024

Novo Nordisk to Present Promising New Data on Sickle Cell Disease at ASH Annual Meeting

Novo Nordisk is set to share groundbreaking data from its HIBISCUS phase 2 trial at the 66th Annual Meeting of the American Society of Hematology (ASH) in San Diego. This …

OxyDial

Nov 28 2024

AB Science Receives European Patent for Masitinib in Sickle Cell Disease Treatment

AB SCIENCE USA, LLC announced that it has received a notice of allowance from the European Patent Office for a patent covering the use of masitinib, an oral therapy in …

OxyDial

Nov 13 2024

KIND Gets FDA Orphan Drug Designation for Sickle Cell Disease Treatment

KINDPharmaceutical, a biotech company, announced that the FDA has granted Orphan Drug Designation to their drug AND017 for treating sickle cell disease. AND017 is being developed by KIND to treat …